In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will get ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or even the individuals are not able to tolerate the study drugs. - Participant eaten grapefruit or grapefruit items within three times prior to https://alfredx232jpa2.blogrenanda.com/profile